Premium
Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancer
Author(s) -
de GeusOei LioeFee,
van der Heijden Henricus F.M.,
Corstens Frans H.M.,
Oyen Wim J.G.
Publication year - 2007
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22979
Subject(s) - medicine , positron emission tomography , lung cancer , fluorodeoxyglucose , context (archaeology) , cancer , predictive value , standardized uptake value , radiology , oncology , disease , pet ct , paleontology , biology
For several years, molecular imaging with 18 F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) has become part of the standard of care in presurgical staging of patients with nonsmall‐cell lung cancer (NSCLC), focusing on the detection of malignant lesions at early stages, early detection of recurrence, and metastatic spread. Currently, there is an increasing interest in the role of FDG‐PET beyond staging, such as the evaluation of biological characteristics of the tumor and prediction of prognosis in the context of treatment stratification and the early assessment of tumor response to therapy. In this systematic review, the literature on the value of the evolving applications of FDG‐PET as a marker for prediction (ie, therapy response monitoring) and prognosis in NSCLC is addressed, divided in sections on the predictive value of FDG‐PET in locally advanced and advanced disease, the prognostic value of FDG‐PET at diagnosis, after induction treatment, and in recurrent disease. Furthermore, the background and recommendations for the application of FDG‐PET for these indications will be discussed. Cancer 2007. © 2007 American Cancer Society.